The story of Sildenafil presents a complex picture for shareholders. While the initial introduction generated significant profits, the lapse of its intellectual property protection opened the floodgates to generic alternatives, dramatically diminishing sales. This creates a specific dilemma for pharmaceutical companies relying on related blockbuste

The history of Viagra, and its creator copyright, presents a challenging case study for investors. Initially a blockbuster drug, yielding billions in income, its patent expiration created a wave of generic competition , significantly eroding its position . While some businesses may attempt to capitalize on similar conditions , the existing landscap